New: Instantly spot drawdowns, dips, insider moves, and breakout themes across Maps and Screener.

Apogee Therapeutics

Contributing Author

Recent Articles by Apogee Therapeutics

Jan-06	Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and Outlook APGE GlobeNewswire
Jan-05	Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026 APGE GlobeNewswire
Nov-10	Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results APGE GlobeNewswire
Nov-10	Apogee Therapeutics Announces Positive Interim Phase 1 Results from Healthy Volunteer Trial of APG333, its Novel Half-Life Extended TSLP Antibody APGE GlobeNewswire
Nov-03	Apogee Therapeutics to Participate in Upcoming Conferences APGE GlobeNewswire
Oct-10	Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million APGE GlobeNewswire
Oct-08	Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering APGE GlobeNewswire
Oct-08	Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering APGE GlobeNewswire
Sep-11	Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress APGE GlobeNewswire
Sep-03	Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum APGE GlobeNewswire
Aug-11	Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results APGE GlobeNewswire
Jul-07	Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis APGE GlobeNewswire
Jul-06	Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025 APGE GlobeNewswire
May-29	Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference APGE GlobeNewswire
May-12	Apogee Therapeutics Provides Business Update, Pipeline Progress and Reports First Quarter 2025 Financial Results APGE GlobeNewswire
May-12	Apogee Therapeutics Announces Positive Interim Results from the Phase 1b Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody, in Patients with Mild-to-Moderate Asthma APGE GlobeNewswire
May-01	Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference APGE GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.